Natural antigen presenting cells (APC) play a critical role in the body’s immune system as they direct the immune system cells in attacks on specifically targeted antigens and cells. However, under certain disease conditions, natural APC can be damaged, dysfunctional or absent. The AIM technology has been designed to orchestrate specific immune system responses in a highly controllable and reproducible way independent of the functional effectiveness or abundance of the patient’s natural APC.Central to the AIM technology is the artificial Antigen Presenting Cell (aAPC) which has four components: (i) the nanoparticle that serves as a synthetic cellular core; (ii) a recombinant HLA construct that “presents” a specific antigen to T cells (Signal 1); (iii) the antigen to stimulate a specific cytotoxic T cell response; and, (iv) a co-stimulatory molecule that facilitates activation of T cells (Signal 2).
The AIM technology holds great potential for use in immunotherapy because aAPC can be readily engineered in such a way that a highly specific immune attack can be directed toward any foreign substance or cell type in a patient’s body.
AIM aAPCs can be loaded with several different antigens in order to stimulate T cell populations that are simultaneously directed at multiple specific disease-associated antigens. These aAPC cocktails can be delivered in vivo as an injected pharmaceutical product, or, for the stimulation T cells ex vivo that can be delivered as an adoptive T cell product.
Acquired by a Consortium of Private Investors Led by Former Celgene
and Medtronic CEOs
Novel Approach to Adoptive Immunotherapy Developed by NexImmune’s Scientific Co-Founders
Technology provides rapid validation of patient-specific neoantigens as potential targets for individualized cancer therapy
NexImmune Attends 2017 JP Morgan Health Care Conference Week, January 8-12, 2017 in San Francisco, California.
Enables Novel Adoptive Immuno-therapy Approach for the Treatment of Cancer